ZYUS Life Sciences Corporation
ZYUS.V
TSX
| 03/31/2026 | 09/30/2025 | 06/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -- | 10.23% | 10.17% | 10.17% | 18.71% |
| Total Depreciation and Amortization | -- | -5.96% | -7.40% | -7.40% | -1.82% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -- | -3.55% | -2.22% | -2.22% | -22.44% |
| Change in Net Operating Assets | -- | -146.13% | 84.68% | 84.68% | 105.42% |
| Cash from Operations | -- | -32.89% | 31.65% | 31.65% | 41.68% |
| Capital Expenditure | -- | 95.87% | 95.43% | 95.43% | 95.53% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | 0.99% | 0.99% | 0.99% | 1,413.75% |
| Cash from Investing | -- | 17.24% | 18.97% | 18.97% | -31.42% |
| Total Debt Issued | -- | 1,477.57% | 2,140.25% | 2,140.25% | -60.36% |
| Total Debt Repaid | -- | 90.65% | -118.06% | -118.06% | 34.82% |
| Issuance of Common Stock | -- | -100.00% | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -- | 1,513.24% | 1,090.26% | 1,090.26% | -47.40% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -- | 100.57% | 98.40% | 98.40% | -437.66% |